Alpha 2.0
Login Register
» Authors » Siddabathuni Nageswaramma

Siddabathuni Nageswaramma

Explore the profile of Siddabathuni Nageswaramma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 3
Followers 0
Related Specialties
General Medicine
Biomedical Engineering
Top 10 Co-Authors
John T Ramapuram
K Sunil Naik
Vinay Kulkarni
Milind Bhrusundi
S Anuradha
Kulkarni Milind Madhukarrao
Anant S Pilawan
Ameet Dravid
Dnyanesh N Morkar
Keyur Shah
Published In
Medicine (Baltimore)
Pragmat Obs Res
Cureus
Affiliations
Soon will be listed here.
Recent Articles
1.
The Efficacy and Safety of High Dose (10 mg) of Desloratadine (Dazit® 10) in the Treatment of Chronic Spontaneous Urticaria in India: A Phase III, Multicentric, Open-Label, Single-Arm Study
Kapadia S, Nageswaramma S, Shah K, Singh A, Mahajan S, Deshpande A, et al.
Cureus . 2024 Feb; 16(1):e53125. PMID: 38420062
Background: Chronic spontaneous urticaria (CSU) is a debilitating affliction that affects diverse quality of life (QoL) parameters such as sleep, self-esteem, and daily activities. Second-generation antihistamines, such as desloratadine, are...
2.
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial
Dravid A, Pilawan A, Anuradha S, Morkar D, Ramapuram J, Madhukarrao K, et al.
Medicine (Baltimore) . 2023 Nov; 102(44):e35643. PMID: 37933062
Background: A randomized interventional phase 4 study in the Indian population confirmed the non-inferiority of the combination tenofovir/lamivudine/efavirenz (TLE)-400 to TLE600. The current manuscript describes in detail the safety profile...
3.
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
Dravid A, Pilawan A, S A, Morkar D, Ramapuram J, Madhukarrao K, et al.
Medicine (Baltimore) . 2022 Dec; 101(48):e31982. PMID: 36482530
Background: To evaluate the non-inferiority of low dose efavirenz (400 mg) to standard dose efavirenz (600 mg), when taken in combination with tenofovir and lamivudine in Indian patients with HIV-1...
4.
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1
Dravid A, Morkar D, Prasad D, Ramapuram J, Patel K, Naik K, et al.
Pragmat Obs Res . 2022 Aug; 13:75-84. PMID: 35975180
Purpose: WHO recommends dolutegravir (DTG) based regimens as first-line treatment for HIV-1 infection. However, few studies have been conducted in Indian population. Hence, our study evaluated the safety, tolerability, and...